Nature Search

The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial

In a randomized trial, treatment of patients with heart failure with an antibody designed to activate the guanylate cyclase receptor NPR1 led to an unexpected increase in NT-proBNP levels and worsening heart failure events compared with the control, prompting termination of the trial.

Scott D. Solomon
John J. V. McMurray
Martin P. Lefkowitz
ResearchOpen Access30 Mar 2026
Nature Medicine

P: 1-7
Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction

In a cross-trial analysis, combined treatment with medications that have individually shown to improve cardiovascular outcomes in heart failure with mildly reduced or preserved ejection fraction demonstrates substantial benefit, including for event-free survival.

Muthiah Vaduganathan
Brian L. Claggett
Scott D. Solomon
ResearchOpen Access06 Oct 2025
Nature Medicine

Volume: 32, P: 325-331
A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials

Post hoc analysis of the DAPA-HF and DELIVER trials reports on the approach of win statistics to evaluate the effect of dapagliflozin on a hierarchical composite kidney outcome in patients with heart failure.

Toru Kondo
Pardeep S. Jhund
John J. V. McMurray
ResearchOpen Access06 May 2024
Nature Medicine

Volume: 30, P: 1432-1439
Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial

In the second season of a series of pragmatic trials involving all Danish citizens 65 years of age or older, electronic nudges increased influenza vaccination rates significantly with respect to usual care, with higher effect in individuals not vaccinated in the previous season.

Niklas Dyrby Johansen
Muthiah Vaduganathan
Tor Biering-Sørensen
Research30 Aug 2024
Nature Medicine

Volume: 30, P: 3142-3149
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.

Orly Vardeny
James C. Fang
Scott D. Solomon
ResearchOpen Access15 Dec 2022
Nature Medicine

Volume: 28, P: 2504-2511
A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram

Deep learning can automate the interpretation of medical imaging tests. Here, the authors formally assess the interchangeability of deep learning algorithms with expert human measurements for interpreting echocardiographic studies.

Jasper Tromp
David Bauer
Scott D. Solomon
ResearchOpen Access09 Nov 2022
Nature Communications

Volume: 13, P: 1-9
Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development

The pathobiology of heart failure (HF) is incompletely understood. The authors identify 37 circulating proteins and 5 protein modules associated with HF risk, with several demonstrating causal effects on HF, risk factors, or cardiac dysfunction by Mendelian randomization analysis.

Amil M. Shah
Peder L. Myhre
Bing Yu
ResearchOpen Access15 Jan 2024
Nature Communications

Volume: 15, P: 1-18
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Muthiah Vaduganathan
Gerasimos Filippatos
Scott D. Solomon
Amendments and CorrectionsOpen Access28 Oct 2024
Nature Medicine

Volume: 30, P: 3778
Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection

Through analysis of the electronic medical records of 284,592 vaccinated patients, using a sequence–symmetry analysis, Kwan et al. show that the risk of postural orthostatic tachycardia syndrome (POTS) is increased after COVID-19 vaccination compared to a 90-day control period before exposure—although 5.35 times lower than the risk of POTS occurrence after SARS-CoV-2 infection.

Alan C. Kwan
Joseph E. Ebinger
Susan Cheng
Research12 Dec 2022
Nature Cardiovascular Research

Volume: 1, P: 1187-1194
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

This participant-level pooled analysis of the three phase 3 trials that have tested the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes provides an integrated view of the mortality, cardiovascular and renal effects of this treatment.

Muthiah Vaduganathan
Gerasimos Filippatos
Scott D. Solomon
ResearchOpen Access01 Sept 2024
Nature Medicine

Volume: 30, P: 3758-3764
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

A pre-specified meta-analysis of pooled, individual patient-level data from the DELIVER and DAPA-HF trials, testing dapagliflozin in patients with heart failure, demonstrates reductions in risk of cardiovascular-associated deaths and hospital admissions for heart failure, regardless of ejection fraction.

Pardeep S. Jhund
Toru Kondo
John J. V. McMurray
ResearchOpen Access27 Aug 2022
Nature Medicine

Volume: 28, P: 1956-1964

Search

Filter By:

Search

Quick links